When administered in mice inoculated with LLC cells, the treated mice show significantly improved muscular atrophy through the inhibition of the myostatin and Smad signaling pathway resulting in lowered muscle atrophy mediators such as MuRF1, F-box only protein 31, and MAFbx/atrogin-1 [176]. Here, FBXO32 is linked to muscular atrophy.